Tratamiento del carcinoma hepatocelular avanzado

Rodríguez De Lope, Carlos; Forner, Alejandro; Bruix, Jordi; Reig, María.
Gastroenterol. hepatol. (Ed. impr.) ; 33(6): 461-468, Jun. -Jul. 2010. ilus, tab
Artículo en Español | IBECS (España) | ID: ibc-84837

Documentos relacionados

  1. Tumor-associated macrophages trigger MAIT cell dysfunction at the HCC invasive margin.
  2. Mechanisms and disease consequences of nonalcoholic fatty liver disease.
  3. Mechanisms of Pharmacoresistance in Hepatocellular Carcinoma: New Drugs but Old Problems.
  4. Multifocal Hepatocellular Carcinoma in a Malayan Wreathed Hornbill (<i>Rhyticeros undulatus</i>).
  5. Arginine reprograms metabolism in liver cancer via RBM39.
  6. Risk thresholds for patients to switch between daily tablets and biweekly infusions in second-line treatment for advanced hepatocellular carcinoma: a patient preference study.
  7. Transarterial Radioembolization for Management of Hepatocellular Carcinoma.
  8. Outcome of patients with HCC and liver dysfunction under immunotherapy: a systematic review and meta-analysis.
  9. Carnosine regulation of intracellular pH homeostasis promotes lysosome-dependent tumor immunoevasion.
  10. Challenges and Future Trends of Hepatocellular Carcinoma Immunotherapy.